LOS ANGELES, CA — (Marketwire) — 03/25/13 — (OTCQB: MMRF) (“MMR”), a leading provider of (“PHRs”), storage solutions and electronic document management and imaging systems for , today announced the launch of seamless connectivity between the MyMedicalRecords Personal Health Record and Electronic Medical Record (“EMR”) systems in medical clinics starting April 15, 2013. The new features facilitate connectivity with any EMR or EHR system and also laboratory reporting systems. Using an HL7 interface, MMR will be able to populate data, such as a Continuity of Care Document (“CCD”), directly to the patient as well as lab test results, medication lists and other discrete data which will be directly deposited into the MyMedicalRecords PHR. At the option of the patient, the system will also be able to push PDFs and other personally managed health information from the patient-s confidentially maintained files directly into an EMR or EHR. The April 15th deployment is part of a joint development effort with a client using 4medica-s Certified for Meaningful Use Integrated Electronic Health Record (4medica iEHR®); however, the system will be available to any EMR system.
According to MMRGlobal CEO Robert H. Lorsch, “The new connectivity adds significant value to our suite of Personal Health Record products and services for physicians, hospitals and other EMR users. This is the first application of its kind to allow a patient to access medical records collected throughout their life and from multiple physicians and integrate them into their primary care physician-s EHR or EMR system. We believe this will increase adoption of our services by providers and their patients by offering the ability to share electronic data and images of a patient-s medical records in two directions.”
This capability is made possible through MMR-s patented online PHR and extensive healthcare IT patent portfolio. The MyMedicalRecords integrated technology platform allows individuals and families the ability to store, retrieve and share documents, images and other forms of protected health information and vital documents using a variety of methods, including fax, phone and Internet among other protocols without relying on any specific Electronic Medical Record platform to originally populate a user-s account.
The MMR patent portfolio includes seven U.S. patents: Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240, as well as additional patents internationally including Australia, Canada New Zealand, Mexico, Japan and Singapore. The Company also has pending applications in Hong Kong, South Korea, Israel, and European nations. The MMR patent portfolio involves inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. Additional information about the Company-s patents can be found in a report available at . Since publishing the report, the Company-s patents in Canada and Japan were allowed.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user-s account. The Company-s professional offering, , is designed to give physicians- offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin-s lymphoma. To learn more about MMRGlobal, Inc. visit . View demos and video tutorials of the Company-s products and services at .
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management-s expectations, beliefs, intentions, estimates or projections, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company-s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “potential,” “intend,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company-s health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company-s products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market-s acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company-s filings with the Securities and Exchange Commission including disclosures about the Company-s relationship with the Michael Bass Group since 2009. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Michael Selsman
Public Communications Co.
(310) 922-7033
You must be logged in to post a comment Login